Navigation Links
'Cancer Research' Has Published a Paper on the Activity of MM-121, an ErbB3 Inhibitor, in Ligand-dependent Tumors
Date:3/16/2010

Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Cell Signaling Technology, Harvard Medical School and Merrimack Pharmaceuticals collaborated on the MM-121 research. Researchers looked at MM-121 in combination with Erbitux to study efficacy in preclinical cancer models resistant to other targeted therapies.

Cambridge, Mass. (PRWEB) March 16, 2010 -- "Cancer Research" has published the paper “MM-121 Demonstrates in vivo Efficacy in Ligand-Dependent Tumors.” The paper describes how MM-121, an ErbB3 inhibitor, is effective as a single agent in preclinical models of cancer that are driven by known cancer-associated ligands within the cell. The researchers also found that combining MM-121 with an EGFR inhibitor showed efficacy in preclinical cancer models that are resistant to other targeted therapies. The work was completed through a collaboration between Merrimack Pharmaceuticals, Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, the Dana-Farber/Harvard Cancer Center, Cell Signaling Technology and Harvard Medical School. MM-121’s novel mechanism, designed using a systems biology approach, promises to benefit patients not effectively treated by current therapies targeting overexpressed or mutated oncogenes. Merrimack and sanofi-aventis are currently enrolling patients in a Phase 1
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
2. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
3. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
4. Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
5. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
6. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
7. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
8. Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
9. New Report Just Published: World Prostate Cancer Therapeutics Market Report
10. New Report Just Published: World Endoscopy Systems Market Report
11. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Cancer Research' Has Published a Paper on the Activity of MM-121, an ErbB3 Inhibitor, in Ligand-dependent Tumors
(Date:6/17/2013)... New York, NY (PRWEB) June 17, 2013 ... to announce the launch of the Chief Medical Officer Summit ... CMO West will take place in San Francisco on ... , For the first time, West Coast Chief Medical ... idea from Dr. Elizabeth Stoner, Managing Director of MPM Capital. ...
(Date:6/17/2013)... 17, 2013 Z Trim Holdings, Inc. ... providing value-added ingredients to a variety of industries, ... new meat application at this year,s annual Institute ... Chicago , July 13-16. The Company will ... expensive/chemically-modified ingredients in meat products thereby helping manufacturers ...
(Date:6/17/2013)... June 17, 2013 ... announced the addition of the "North ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics- Forecasts ... ,      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:6/17/2013)... As interest increases in developing novel biomarker and ... need to keep up with the pace of new ... first in a series titled “Better Methods for Novel ... range of technologies, introduces a novel method for more ... than either ELISA or traditional LCMS can achieve. , ...
Breaking Biology Technology:Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3Quantitative Analysis of Biomarkers, New Life Science Webinar Hosted by Xtalks 2
... SANTA BARBARA, Calif., Nov. 15, 2011 FindTheBest,s Private ... parents seeking an accredited storage facility for their newborn,s cord ... and highly sensitive decision to make, particularly for families with ... parents a way to make the most informed decision when ...
... N.J., Nov. 15, 2011 Palatin Technologies, Inc. (NYSE ... targeted, receptor-specific peptide therapeutics for the treatment of diseases ... announced results for its first quarter ended September 30, ... or $(0.10) per basic and diluted share, for the ...
... 2011 A new retrospective subanalysis ... mesylate) capsules 150mg twice daily reduced the risk ... in patients with non-valvular atrial fibrillation (NVAF) irrespective ... with no significant interaction for major bleeding events.(1) ...
Cached Biology Technology:Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 2Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 3Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 4Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 5New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 2New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 3New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 4New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 5New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 6New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 7New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 8
(Date:6/17/2013)... 2013 An international team led by scientists at ... Institute and Albert Einstein College of Medicine of Yeshiva ... that attacks the tuberculosis (TB) bacterium in two different ... solve one of the major global health crises of ... strains," said Peter G. Schultz, the Scripps Family Chair ...
(Date:6/17/2013)... professors in Wayne State University,s Department of Physics ... Research Experience for Undergraduates (REU) program. This program ... cutting-edge research in astrophysics, and in particle and ... Ph.D., professor of physics in Wayne State,s College ... director of the grant, the student participants will ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Wayne State welcomes undergraduates from around the US for physics research experience 2'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... DNA mutations may shepherd in an era of small, ... of genes that harbor disease. , Joseph Wang, director ... Biodesign Institute at ASU, led a team effort that ... and nanotechnology to fashion nanocrystals that can act as ...
... the plagues of the Middle Ages have made around 10% ... time that these individuals carry a genetic mutation (known as ... the immune system but have been unable to account for ... low levels in areas bordering the Mediterranean. , They have ...
... team of researchers at Johns Hopkins Medical Institutions in ... (PET/CT) scans may help physicians identify new, unexpected malignant ... the May issue of the Society of Nuclear Medicine's ... additional lesions in patients known to have cancer," said ...
Cached Biology News:Bioelectronic ‘signatures?hold key to DNA mutations 2First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes 2PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment 2
...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: